157 related articles for article (PubMed ID: 11976818)
21. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
[TBL] [Abstract][Full Text] [Related]
22. Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Musch E; Malek M; Chrissafidou A
Ann Hematol; 2003 Apr; 82(4):244-6. PubMed ID: 12707729
[TBL] [Abstract][Full Text] [Related]
23. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
24. Amifostine exerts anti-angiogenic activity and suppresses vascular endothelial growth factor secreted by hemopoietic stem/progenitor cells.
Akel SM; Atoum MF; Saleh SA; Awadallah SM
Saudi Med J; 2005 Oct; 26(10):1523-8. PubMed ID: 16228049
[TBL] [Abstract][Full Text] [Related]
25. Amifostine has the potential to induce haematologic responses and decelerate disease progression in individual patients with low- and intermediate-1-risk myelodysplastic syndromes.
Schanz J; Jung H; Wörmann B; Gassmann W; Petersen T; Hinke A; Haase D
Leuk Res; 2009 Sep; 33(9):1183-8. PubMed ID: 19411105
[TBL] [Abstract][Full Text] [Related]
26. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human erythropoietin in the treatment of myelodysplastic syndromes. An interim report.
Aloe Spiriti MA; Petti MC; Latagliata R; Avvisati G; De Gregoris C; Proia S; Fazi P; Jaalouk G; Mancini M; Spadea A
Haematologica; 1993; 78(2):123-6. PubMed ID: 8349188
[TBL] [Abstract][Full Text] [Related]
28. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
29. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
30. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
Ljung T; Bäck R; Hellström-Lindberg E
Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
[TBL] [Abstract][Full Text] [Related]
31. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
32. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
[TBL] [Abstract][Full Text] [Related]
33. Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
Grossi A; Musto P; Santini V; Balestri F; Fabbri A; Falcone A; Sanpaolo G
Haematologica; 2002 Mar; 87(3):322-3. PubMed ID: 11869946
[TBL] [Abstract][Full Text] [Related]
34. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.
List AF; Brasfield F; Heaton R; Glinsmann-Gibson B; Crook L; Taetle R; Capizzi R
Blood; 1997 Nov; 90(9):3364-9. PubMed ID: 9345018
[TBL] [Abstract][Full Text] [Related]
35. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
36. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
[TBL] [Abstract][Full Text] [Related]
37. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
González-Barón M; Ordóñez A; Franquesa R; Constenla M; Montalar J; Gili F; Camps C; Sancho JF; Pérez-Cachot P
Cancer; 2002 Dec; 95(11):2408-13. PubMed ID: 12436449
[TBL] [Abstract][Full Text] [Related]
38. Successful treatment of refractory anemia by high-dose methylprednisolone associated with an increment in CD68-positive cells in bone marrow.
Motomura S; Motoji T; Okutomi K; Nishikawa T; Kasajima T; Mizoguchi H
Am J Hematol; 2001 Feb; 66(2):80-4. PubMed ID: 11421303
[TBL] [Abstract][Full Text] [Related]
39. Cyclosporin A in myelodysplastic syndrome: a preliminary report.
Dixit A; Chatterjee T; Mishra P; Choudhary DR; Mahapatra M; Saxena R; Choudhry VP
Ann Hematol; 2005 Sep; 84(9):565-8. PubMed ID: 15809884
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
